Samrat Pharmachem Reports FY26 Revenue Growth Amid EBITDA Contraction

Revenue grew marginally to Rs 289.72 crore, while EBITDA swung to a loss of Rs 3.94 crore.

Reader Takeaway: Management is focusing on product portfolio expansion to drive recovery from current operating losses.

What just happened

Samrat Pharmachem Ltd held its 34th Annual General Meeting on September 23, 2026, via video conferencing. The company presented its financial performance for the fiscal year 2026, detailing a modest rise in top-line growth alongside a challenging shift in operating profitability. Management confirmed a capital expenditure of Rs 6.29 crore during the year, aimed at bolstering production capacity for both domestic and export markets.

Why this matters

The transition from a positive EBITDA of Rs 11.87 crore in the previous year to a loss of Rs 3.94 crore reflects significant pressure on core business margins. For shareholders, this reversal highlights a need for greater efficiency as the company integrates its recent capital investments. The management’s stated intent to add new products is intended to stimulate growth, but the timeline for this impact on the bottom line remains the primary focus for stakeholders.

Governance and Audit

While the statutory audit for FY26 was reported as unqualified, the secretarial audit was qualified. These qualifications, which address specific compliance or governance observations, were presented by the Scrutinizer during the AGM. Investors typically view secretarial qualifications as a signal to review corporate compliance health more closely.

What to track next

• Operating Margins: Monitoring whether upcoming product additions successfully translate into a return to positive EBITDA.
• Compliance Updates: Observing any management action taken to address the observations noted in the qualified secretarial audit report.
• Capex Efficiency: Evaluating if the Rs 6.29 crore investment yields the expected growth in production output in the coming quarters.